Global Head, Pricing & Market Access,
GSK

Dr. Diana Brixner is Emeritus Professor in the Department of
Pharmacotherapy and is a Founder of the Pharmacotherapy
Outcomes Research Center (PORC) at the University of Utah
in Salt Lake City, UT. She has been a member of both the
Huntsman Cancer Institute Cancer Control and Population
Sciences and the Center for Genomic Medicine. She also
serves as a principal of the Millcreek Outcomes Group, LLC where she consults on
translating evidence to value to support payer decision making. Prior to her
academic appointment in 2002 she worked both in the biotech (NeoRx) and
pharmaceutical (SmithKline Beecham, Novartis) industry focused on value
assessment of their technologies in the early years of the field. Dr. Brixner was a Past President of both the Academy of Managed Care Pharmacy (AMCP) and
International Society of Pharmacoeconomics and Outcomes Research (ISPOR). She
has served as a one-year Scholar-in-Residence for the Academy of Managed Care
Pharmacy, recently served on the scientific advisory board of Lumanity and is a
member of the Executive Board of the International Market Access Society.
Education & Training:
Dr. Brixner received her B.S. degree in 1982 from the University of Rhode Island,
Pharmacy. In 1987 she received her Ph.D. in Medicinal Chemistry from the
University of Utah. She received a Modeling Approaches for Health Technology
Assessment Certificate in 2010, a Clinical Epidemiology Certificate in 2013 and a
Certificate in the Introduction to Health Technology Assessment in 2015 from the
University of Health Sciences, Medical Informatics and Technology, Hall in Tirol,
Austria where she did a sabbatical in 2011.
Research Interests:
Dr. Brixner's research focus is on the design, conduct, and communication of
pharmacoeconomic and outcomes research studies to demonstrate the value of
pharmaceutical and related therapies from the perspective of the private and public payer. Much of her work is focused on oncology and personalized medicine. She has published over 150 articles in peer-reviewed journals, authored three book chapters, has one issued patent, and has been an invited speaker at a variety of national and international professional meetings.
Publications: Diana Brixner Publication list PubMed
Email: diana.brixner@utah.edu

Professor, Institute for Hospital Management, Tsinghua University

President, Chief Strategist,
Passage Health Associates

Professor Emeritus,
University of Washington

Senior Vice President & Head, US Market Access, Astra-Zeneca

EVP & Chief Commercial Officer,
Cormedix

Dr. Shadi Saleh is Founding Director of the Global Health Institute (GHI) at the American University of Beirut (AUB), the first such institute in the Middle East and North Africa region. In addition, he is a Professor of Health Systems and Financing. Previously, he served as an Associate Vice President for Health Affairs and as the Chairman of the Department of Health Management at Policy at AUB; and as a Professor of Health Systems at the State University of New York.
Dr. Saleh’s areas of expertise are in evidence-based decision-making in health care, health system strengthening and financing and health economics and outcomes research (HEOR), with a focus on the pharmaceutical sector.  He has published over 150 peer-reviewed papers and commissioned reports, including publications in the Lancet, American Journal of Public Health and Medical Care among others.
Dr. Saleh served as an elected board member of the Consortium of Universities in Global Health; He is also a Head of Delegation with the M8 Alliance and an Executive Board Member of the International Market Access Society. Dr. Saleh served as an appointed member of the National Emergency Social Protection Project and the Committee on Universal Health Coverage with the Ministry of Public Health in Lebanon. Dr. Saleh also serves as a World Bank, WHO and UN advisor for health care financing policy and system strengthening projects. In 2022, he was awarded the Velji Award for Global Health Leadership.
Shadi Saleh holds a PhD in Health Policy (minor in health care finance) from the University of Iowa and a Masters of Public Health (health services administration) and a BS from AUB.

Dr. Michael Sherman is Principal at Sherman Healthcare Solutions, LLC, offering consulting, fractional executive-level support, and independent board service in the healthcare industry. He is also on faculty at Harvard Medical School’s Department of Population Medicine. Additionally, Dr. Sherman advises RA Capital Management, a $10 billion multi-stage investment manager focused on healthcare and life sciences. Before becoming an advisor in May 2025, he was a full-time venture partner at RA.

Dr. Sherman has served as executive vice president and chief medical officer at Point32Health, formed by the merger of Harvard Pilgrim Health Care and Tufts Health Plan, covering over 2 million members. Previously, as chief medical officer of Harvard Pilgrim, he gained recognition for innovation and quality, pioneering access to transformational therapeutics, precision medicine, and digital therapeutics. His initiatives included launching pilots that balanced access and affordability, generating real world evidence noted nationally.
In 2018 Dr. Sherman received Xconomy’s “Contrarian Award” for developing the nation’s first value-based gene therapy payment model, and his work is highlighted in a 2021 Harvard Business School case study. Dr. Sherman led efforts to expand access to precision medicine, such as whole genome screening, and made his organization the first to cover the GRAIL Galleri Multi-Cancer Early Detection Blood Test for select commercial members in 2022.

Dr. Sherman’s previous roles include serving as corporate medical director for physician strategies at Humana, as well as leadership roles at United Healthcare, Thomson Medstat, Immusol, and other firms.

Dr. Sherman holds an M.B.A. from Harvard Business School, an M.D. from Yale, and a B.A. in Anthropology and Natural Sciences plus an M.S. in Biomedical Anthropology from the University of Pennsylvania. He regularly speaks at major conferences, lectures at Harvard Medical School, and has provided legislative testimony at the national level, including at the White House and Capitol Hill.

Principal, Rubix Health
Senior Fellow, CVER

Senior Director, Market Access & Payment Policy, Becton, Dickinson & Company

Chief Scientific Officer, ACCESS Forum
CEO, curestack

Chief Commercial Officer,
MUVON Therapeuatics AG

President, Market Access,
Real Chemistry

Head Global Market Access Operations Excellence, Takeda

Myoung Kim, Ph.D., M.A., M.B.A. brings over 25 years of experience in health economics and outcomes research (HEOR) and observational research. Prior to Annexon, Dr. Kim was vice president and head of U.S. HEOR, real world evidence and population health at Novartis, where she led office- and field-teams spanning the entire portfolio. Prior to that she served a similar role as vice president of real-world value and evidence at Janssen Pharmaceuticals where she led value evidence generation and communication across the Janssen portfolio. Early in her career she also held increasing roles of responsibility at J&J Medical Devices and held positions at Bristol-Myers Squibb, Bayer Corporation, and Merck & Co.  Dr. Kim holds a Ph.D. and an M.A. in health economics and policy from The Wharton School at the University of Pennsylvania. She also earned an M.B.A. of international business from the University of South Carolina and a B.A. from Seoul National University in Seoul, South Korea.

Clinical Associate Professor, Lebanese American University, School of Pharmacy

Parashar is an accomplished healthcare executive with a demonstrated history of leadership in the medical device industry and public sector. He brings more than 30 years of health policy and market access experience to clients.

Parashar develops efficient and effective plans to engage stakeholders, including healthcare policymakers and payers in the United States and abroad. His areas of expertise include payment and coverage policy, market access strategies, healthcare delivery systems, medical devices and clinical research.

Prior to joining McDermottPlus, Parashar served as senior vice president for government affairs and market access at ViewRay, where he led global efforts to drive adoption of MRIdian in cancer treatment. He previously led Boston Scientific’s global teams focused on the development and execution of market access, health economics and public policy strategies for key technologies.

Parashar also held a variety of roles at the Centers for Medicare and Medicaid Services, the American Association of Health Plans, the Office of (then) Senate Majority Leader George J. Mitchell and the US Office of Management and Budget.

Professor, Pharmacy Systems, Outcomes & Policy, College of Pharmacy, University of Illinois at Chicago

Vice President & Global Head of HEOR,
Alcon

At Cepheid, Dr. Schroeder leads efforts focused on developing Market Access strategies to drive medical and public policy for Cepheid’s clinical applications in Infectious Diseases, Women’s and Sexual Health, Virology, Healthcare Associated Infections and Oncology globally, and is responsible for driving engagements with payers, the commercial organization and our Lab customers in the Americas. Prior to Cepheid, Brock was Vice President of Market Access at Illumina, where he led efforts to demonstrate the compelling value of next-generation sequencing (NGS)-based clinical applications to payers and health technology assessment (HTA) agencies globally supported by robust clinical and economic evidence to maximize and accelerate patient access and improve health outcomes. Prior to Illumina, Brock led Medical & Scientific Affairs at Biotheranostics (since acquired by Hologic), where his team focused on generating and communicating evidence supporting the clinical and economic utility of 2 proprietary molecular diagnostic assays in the oncology therapeutic area--leading to US Medicare coverage for both assays. Brock's industry experience includes multiple therapeutic areas including oncology, rare disease, reproductive health, infectious diseases, and metabolic disorders. Brock received his BA in Biology from Washington University and his PhD in Neuroscience from the University of Wisconsin-Madison.

Noreen has more than 30 years of experience in the healthcare industry, including 20 years in commercial roles at Bristol Myers Squibb and DuPont Pharmaceutical Company and more than 15 years in strategic consulting, global market access, and HEOR.

Prior to joining IQVIA, Noreen held senior leadership positions at Evidera/PPD/ThermoFisher Scientific, Kantar Health/WPP, and Ipsos Healthcare, where she served as a Client Officer and Trusted Advisor. Her expertise covers key areas such as pricing, reimbursement, and market access; integrated evidence generation plan development; value messaging; payer and KOL insights; and patient advocacy and patient voice.

Her areas of expertise include global health policy, including the Inflation Reduction Act and JCA. Noreen's therapeutic background spans oncology, cardiology, neurology, respiratory, infectious disease, endocrinology, ophthalmology, vaccines, rare disease, cell and gene therapy, and companion diagnostics.

Noreen holds a Bachelor of Science in Business Administration with an emphasis in Marketing from Northeastern University, Boston, MA.

In her current role, Noreen provides comprehensive strategic solutions in pricing, reimbursement, and market access to support cross-functional priorities within each client. She brings extensive knowledge in global market access, HEOR, commercial, RWE, and patient advocacy. Noreen assists clients in developing and executing pricing, reimbursement, and market access strategies, as well as integrated evidence generation plans that support key value dimensions for payers and other stakeholders in both US and global markets. She also serves as senior advisor on client engagements supporting strategic partnerships and ensuring project success.

Chief Executive Officer,
GTannus Group

LATAM Regional Market Access Director,
Hematology,
J&J

Yoojung Yang, based in Boston, MA, US, is currently a Senior Director, Head of North America HEOR at Vertex Pharmaceuticals. Yoojung Yang brings experience from previous roles at MedImmune, Vertex Pharmaceuticals and Baxalta. Yoojung Yang holds a 2018 - 2018 Certificate in Portfolio Leadership @ The Wharton School. With a robust skill set that includes Outcomes Research, Health Economics, Pharmacoeconomics, Pharmacy, HTA and more. Yoojung Yang has 2 emails on RocketReach.

Global Value & Access Lead,
Takeda Oncology

Dr. Diana Brixner is Emeritus Professor in the Department of
Pharmacotherapy and is a Founder of the Pharmacotherapy
Outcomes Research Center (PORC) at the University of Utah
in Salt Lake City, UT. She has been a member of both the
Huntsman Cancer Institute Cancer Control and Population
Sciences and the Center for Genomic Medicine. She also
serves as a principal of the Millcreek Outcomes Group, LLC where she consults on
translating evidence to value to support payer decision making. Prior to her
academic appointment in 2002 she worked both in the biotech (NeoRx) and
pharmaceutical (SmithKline Beecham, Novartis) industry focused on value
assessment of their technologies in the early years of the field. Dr. Brixner was a Past President of both the Academy of Managed Care Pharmacy (AMCP) and
International Society of Pharmacoeconomics and Outcomes Research (ISPOR). She
has served as a one-year Scholar-in-Residence for the Academy of Managed Care
Pharmacy, recently served on the scientific advisory board of Lumanity and is a
member of the Executive Board of the International Market Access Society.
Education & Training:
Dr. Brixner received her B.S. degree in 1982 from the University of Rhode Island,
Pharmacy. In 1987 she received her Ph.D. in Medicinal Chemistry from the
University of Utah. She received a Modeling Approaches for Health Technology
Assessment Certificate in 2010, a Clinical Epidemiology Certificate in 2013 and a
Certificate in the Introduction to Health Technology Assessment in 2015 from the
University of Health Sciences, Medical Informatics and Technology, Hall in Tirol,
Austria where she did a sabbatical in 2011.
Research Interests:
Dr. Brixner's research focus is on the design, conduct, and communication of
pharmacoeconomic and outcomes research studies to demonstrate the value of
pharmaceutical and related therapies from the perspective of the private and public payer. Much of her work is focused on oncology and personalized medicine. She has published over 150 articles in peer-reviewed journals, authored three book chapters, has one issued patent, and has been an invited speaker at a variety of national and international professional meetings.
Publications: Diana Brixner Publication list PubMed
Email: diana.brixner@utah.edu

Ms. Carranza is a tenured market access leader with expertise in access and reimbursement across oncology, rare diseases, biopharmaceuticals, vaccines, and medical devices. She has worked at industry-leading organizations including Johnson & Johnson Medical Devices, GlaxoSmithKline, AstraZeneca, and Sunovion Pharmaceuticals.
She is skilled in stakeholder engagement, account management strategy, and creating access to drive solutions that focus on patient-centric solutions that enhance outcomes and population health.
As an Access Forum Professional Development Committee Member, Ms. Carranza is committed to mentoring and developing others, fostering knowledge-sharing, and advancing strategies that improve access to care and healthcare outcomes.

Adrian is a global leader in healthcare data, advanced analytics, and evidence generation, with extensive experience spanning both public and private sectors. He has successfully lead high value data and digital transformation strategies at GSK Vaccines, Hoffmann-La Roche, and Novartis, advancing real world applications for product development, payer insights, and clinical adoption. In his current role as Vice President and Head of Global Evidence Generation at Novartis, he leads the development and execution of integrated evidence strategies across diverse modalities and therapy areas shaping the future of evidence-based decision making in healthcare.

Dmitry Goldenberg is a Partner in Simon-Kucher’s global Healthcare & Life Sciences sector and based in the New York City office. He has nearly two decades of experience across the consulting and pharmaceutical industry helping companies develop pricing, market access, and commercial strategy.
Dmitry joined Simon-Kucher after more than 5 years at Pfizer as a member of the Oncology Global Access Strategy & Pricing team, where he developed market access strategy for the breast cancer franchise and led multiple organizational readiness initiatives. During his time at Pfizer, he developed global pricing strategy for multiple brands, created access and commercial brand deliverables, and partnered with more than 40 countries around the world to support payer negotiations.
Prior to joining Pfizer, Dmitry was a Principal in Decision Resources Group’s Consulting division, where he was a member of the leadership team and focused on helping pharmaceutical companies develop US managed care strategy, including pricing, contracting, and reimbursement.
Dmitry has supported clients across all stages of the product lifecycle and has launched products in oncology, rare & orphan diseases, diabetes, and cardiology therapeutic areas. He uses his unique blend of consulting and pharmaceutical industry experience to develop access and commercial strategies that can improve patient outcomes around the world.

Senior Director, Patient Affairs • Global Policy, Government, & Patient Affairs,
Sarepta Therapeutics

Dr. Shadi Saleh is Founding Director of the Global Health Institute (GHI) at the American University of Beirut (AUB), the first such institute in the Middle East and North Africa region. In addition, he is a Professor of Health Systems and Financing. Previously, he served as an Associate Vice President for Health Affairs and as the Chairman of the Department of Health Management at Policy at AUB; and as a Professor of Health Systems at the State University of New York.
Dr. Saleh’s areas of expertise are in evidence-based decision-making in health care, health system strengthening and financing and health economics and outcomes research (HEOR), with a focus on the pharmaceutical sector.  He has published over 150 peer-reviewed papers and commissioned reports, including publications in the Lancet, American Journal of Public Health and Medical Care among others.
Dr. Saleh served as an elected board member of the Consortium of Universities in Global Health; He is also a Head of Delegation with the M8 Alliance and an Executive Board Member of the International Market Access Society. Dr. Saleh served as an appointed member of the National Emergency Social Protection Project and the Committee on Universal Health Coverage with the Ministry of Public Health in Lebanon. Dr. Saleh also serves as a World Bank, WHO and UN advisor for health care financing policy and system strengthening projects. In 2022, he was awarded the Velji Award for Global Health Leadership.
Dr. Saleh holds a PhD in Health Policy (minor in health care finance) from the University of Iowa and a Masters of Public Health (health services administration) and a BS from AUB.

At Cepheid, Dr. Schroeder leads efforts focused on developing Market Access strategies to drive medical and public policy for Cepheid’s clinical applications in Infectious Diseases, Women’s and Sexual Health, Virology, Healthcare Associated Infections and Oncology globally, and is responsible for driving engagements with payers, the commercial organization and our Lab customers in the Americas. Prior to Cepheid, Brock was Vice President of Market Access at Illumina, where he led efforts to demonstrate the compelling value of next-generation sequencing (NGS)-based clinical applications to payers and health technology assessment (HTA) agencies globally supported by robust clinical and economic evidence to maximize and accelerate patient access and improve health outcomes. Prior to Illumina, Brock led Medical & Scientific Affairs at Biotheranostics (since acquired by Hologic), where his team focused on generating and communicating evidence supporting the clinical and economic utility of 2 proprietary molecular diagnostic assays in the oncology therapeutic area--leading to US Medicare coverage for both assays. Brock's industry experience includes multiple therapeutic areas including oncology, rare disease, reproductive health, infectious diseases, and metabolic disorders. Brock received his BA in Biology from Washington University and his PhD in Neuroscience from the University of Wisconsin-Madison.

Dr. Toro is a highly accomplished professional (Physician and Health Economist), with over twenty years of executive experience in Bio/Gene/Pharma industry. Trained in Colombia/Spain/US, he has led HEOR/Access strategies for launching innovative products (many became blockbusters) across emerging and developed markets at global/regional/local levels. An expert in HEOR/RWE, Market Access/Pricing/HTAs, he has had senior leadership roles at AbbVie, Pfizer, and Bayer, mainly focused on Immunology, Oncology (both, solid and hematologic), and Neuroscience. Over the past five years, he has served at Novartis (at both Global and the US levels) supporting the launch and shaping the HEOR strategies for the market’s first blockbuster gene therapy.

Joseph Boswell, President of ACCESS Forum and Founder/President of GenMAV Inc., has been in the healthcare industry for over 25 years.  Rising upthrough pharmaceutical/biotech/medical device world, he worked through progressively higher levels at Wyeth-Ayerst, Johnson and Johnson (where he spent 14 years), and  12 years heading Business Development for Avalere Health in Washington DC before founding his own firm in 2020.  He has developed expertise in a wide array of therapeutic areas (including cardiovascular, diabetes, women’s health, depression, and obesity) as well as broader healthcare trends—especially as they relate to value, evidence and stakeholder engagement in the evolving healthcare marketplace.  He sits on the Boards of LiquidBiosciences and Embic corporations.
Joseph holds a BA in History from the University of California, Los Angeles and a Certificate in Strategic Alliances from Wharton at the University of Pennsylvania. He is a Certified Instructional Designer.

Chief Scientific Officer,
ACCESS Forum

Kome Okposo, PharmD, is a global medical affairs leader with over 25 years of experience in multiple therapeutic areas, including gene therapy in pharma and biotech. As Head of Communications and Learning for ACCESS Forum, he leads the design and delivery of impactful learning experiences, strategic communications, and thought leadership initiatives. With a deep commitment to clarity and connection, Kome ensures that ACCESS Forum’s programs empower professionals across the market access ecosystem with actionable insights and skills. Known for his ability to distill complex topics into engaging narratives, he fosters an environment of continuous learning and purposeful dialogue that advances the Forum’s mission to expand patient access worldwide.

Aya Saleh holds a Bachelor in Health Communication from the American University of Beirut. Professionally, she has built experience in social media management, marketing coordination, and content strategy through roles with organizations such as ACCESS Forum, LA GRAY, the Women Integrated Sexual Health (WISH) Program at AUBMC, and the AUB Global Health Institute.

Aya is passionate about leveraging market insights and creative content strategies to help organizations grow their communities and drive meaningful engagement.

Vipan C. Sood, RPh, MBA, MRPharmS, is a global pharmaceutical leader with over 25 years of experience, consistently driving commercial success through expertise in health economics and outcomes research (HEOR), medical affairs, and market & patient access & reimbursement.

His recent roles include VP, Global and US Head, HEOR at CSL VIFOR Pharma in Zurich; VP of Global Specialty HEOR at AbbVie Inc., and Senior Director, Medical Affairs and HEOR at Mitsubishi Tanabe Pharma America (MTPA), Inc. Prior to that he has held leadership roles at GSK, Pfizer, Merck, and Sanofi.

Vipan excels at strategic planning, operational optimization, and fostering innovation, all while inspiring high-performing teams across diverse therapeutic areas like renal, autoimmune, cardiovascular, virology, and vaccines.